Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis

[1]  H. Xu,et al.  Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1 , 2021, Nature Chemical Biology.

[2]  Liping Zou,et al.  Hypohomocysteinemia may increases the risk of dementia and Alzheimer's disease. , 2021, Clinical nutrition.

[3]  F. Tovar-Moll,et al.  Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer's and Lewy Body Diseases. , 2021, Journal of Alzheimer's disease : JAD.

[4]  Y. Sung,et al.  Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment , 2021, Frontiers in Aging Neuroscience.

[5]  W. Zou,et al.  The MCP-1 A-2518G polymorphism increases the risk of Alzheimer’s disease: A case-control study , 2021, Neuroscience Letters.

[6]  P. Edison,et al.  Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? , 2020, Nature Reviews Neurology.

[7]  Catarina Domingues,et al.  IL-8 and MCP-1 impact on Tau phosphorylation and phosphatase activity. , 2020, Current Alzheimer research.

[8]  A. Słowik,et al.  Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. , 2020, Current Alzheimer research.

[9]  I. Ferrer,et al.  Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis , 2020, International journal of molecular sciences.

[10]  S. Chinnathambi,et al.  Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation , 2020, Cell & bioscience.

[11]  M. Sabbagh,et al.  Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval , 2020, Alzheimer's Research & Therapy.

[12]  Suwen Zhao,et al.  Structural basis of CXC chemokine receptor 2 activation and signalling , 2020, Nature.

[13]  C. Aldasoro,et al.  The Role of Chemokines in Alzheimer's Disease. , 2020, Endocrine, metabolic & immune disorders drug targets.

[14]  M. Salinas-Carmona,et al.  Chemokine profile in Alzheimer’s disease: Results from a Mexican population , 2020, Journal of Clinical Neuroscience.

[15]  W. M. van der Flier,et al.  CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[16]  R. Perneczky,et al.  Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid. , 2020, Journal of Alzheimer's disease : JAD.

[17]  F. Wang,et al.  Chemokine CCL2 contributes to BBB disruption via the p38 MAPK signaling pathway following acute intracerebral hemorrhage , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Anne Brækhus,et al.  The Association Between Circulating Inflammatory Markers and the Progression of Alzheimer Disease in Norwegian Memory Clinic Patients With Mild Cognitive Impairment or Dementia , 2019, Alzheimer disease and associated disorders.

[19]  D. Kabelitz,et al.  Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly. , 2019, Neurodegenerative disease management.

[20]  Magda Tsolaki,et al.  Inflammatory biomarkers in Alzheimer's disease plasma , 2019, Alzheimer's & Dementia.

[21]  Alan J. Thomas,et al.  Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimer’s disease , 2019, International Psychogeriatrics.

[22]  P. Selnes,et al.  Glial activation and inflammation along the Alzheimer’s disease continuum , 2019, Journal of Neuroinflammation.

[23]  K. Nash,et al.  Neuroinflammation and fractalkine signaling in Alzheimer’s disease , 2019, Journal of Neuroinflammation.

[24]  L. Tan,et al.  Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[25]  A. Lleó,et al.  Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease , 2018, Front. Neurosci..

[26]  K. Blennow,et al.  Biomarkers for Alzheimer's disease: current status and prospects for the future , 2018, Journal of internal medicine.

[27]  Taotao Lao,et al.  Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies , 2018, Front. Neurol..

[28]  J. Schott,et al.  Molecular biomarkers of Alzheimer's disease: progress and prospects , 2018, Disease Models & Mechanisms.

[29]  Daxiang Lu,et al.  PYNOD reduces microglial inflammation and consequent neurotoxicity upon lipopolysaccharides stimulation , 2018, Experimental and therapeutic medicine.

[30]  M. Sarazin,et al.  Neutrophil hyperactivation correlates with Alzheimer's disease progression , 2018, Annals of neurology.

[31]  Wei‐Ju Lee,et al.  Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study , 2018, Scientific Reports.

[32]  Y. Hayashi,et al.  Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[33]  Chunyan Zhu,et al.  Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s Disease , 2017, Molecular Neurobiology.

[34]  C. Rowe,et al.  A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort , 2017, Scientific Reports.

[35]  A. Carvalho,et al.  Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[36]  K. Ramasamy,et al.  Peripheral cytokines, C‐X‐C motif ligand10 and interleukin‐13, are associated with Malaysian Alzheimer's disease , 2017, Geriatrics & gerontology international.

[37]  C. Rowe,et al.  Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort , 2017, Alzheimer's & dementia.

[38]  N. Venketasubramanian,et al.  Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer's disease , 2017, Alzheimer's & dementia.

[39]  Amanda G. Smith,et al.  Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients , 2016, Alzheimer's Research & Therapy.

[40]  C. V. von Arnim,et al.  Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β , 2016, BMC Neurology.

[41]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[42]  Paul Edison,et al.  Neuroinflammation in Alzheimer's disease: Current evidence and future directions , 2016, Alzheimer's & Dementia.

[43]  G. Britton,et al.  Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. , 2016, Neurodegenerative disease management.

[44]  M. Álvarez,et al.  Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD? , 2016, Current Alzheimer research.

[45]  Simone Lista,et al.  Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges , 2015, Alzheimer's & dementia.

[46]  J. Hsu,et al.  Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease , 2015, Dementia and Geriatric Cognitive Disorders Extra.

[47]  J. Nahon,et al.  The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects , 2015, Annals of the New York Academy of Sciences.

[48]  T. Rème,et al.  Central Nervous System and Peripheral Inflammatory Processes in Alzheimer’s Disease: Biomarker Profiling Approach , 2015, Front. Neurol..

[49]  L. Minthon,et al.  The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies , 2015, PloS one.

[50]  O. Paulsen,et al.  Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity , 2015, PloS one.

[51]  Tiejun Tong,et al.  Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range , 2015, Statistical methods in medical research.

[52]  Nick C Fox,et al.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[53]  M. Heneka,et al.  CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model. , 2015, The Journal of clinical investigation.

[54]  Teng Jiang,et al.  Microglia in Alzheimer's Disease , 2014, BioMed research international.

[55]  K. Blennow,et al.  Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease , 2014, Dementia and Geriatric Cognitive Disorders Extra.

[56]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[57]  Jiyoung Kim,et al.  Enhancement of CCL15 Expression and Monocyte Adhesion to Endothelial Cells (ECs) after Hypoxia/Reoxygenation and Induction of ICAM-1 Expression by CCL15 via the JAK2/STAT3 Pathway in ECs , 2013, The Journal of Immunology.

[58]  A. Simmons,et al.  Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease , 2013, PloS one.

[59]  P. Bickford,et al.  Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy , 2013, Neurobiology of Aging.

[60]  H. Gendelman,et al.  CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.

[61]  Michael S. McGrath,et al.  Systemic immune system alterations in early stages of Alzheimer's disease , 2013, Journal of Neuroimmunology.

[62]  M. Franceschi,et al.  Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer’s disease , 2013, Immunity & Ageing.

[63]  Magda I. Mohamad,et al.  Histone Deacetylases Enzyme, Copper, and IL-8 Levels in Patients With Alzheimer’s Disease , 2013, American journal of Alzheimer's disease and other dementias.

[64]  D. Llano,et al.  Cerebrospinal Fluid Cytokine Dynamics Differ Between Alzheimer Disease Patients and Elderly Controls , 2012, Alzheimer disease and associated disorders.

[65]  A. Zlotnik,et al.  The chemokine superfamily revisited. , 2012, Immunity.

[66]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[67]  N. Greig,et al.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease. , 2012, Current Alzheimer research.

[68]  Oskar Hansson,et al.  CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease , 2012, PloS one.

[69]  Mattias Ohlsson,et al.  Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease , 2012, PloS one.

[70]  G. Kemmler,et al.  Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy Subjects , 2011, Dementia and Geriatric Cognitive Disorders Extra.

[71]  Ashutosh,et al.  CXCL8 protects human neurons from amyloid-β-induced neurotoxicity: relevance to Alzheimer's disease. , 2011, Biochemical and biophysical research communications.

[72]  R. Ransohoff,et al.  CX3CR1 Protein Signaling Modulates Microglial Activation and Protects against Plaque-independent Cognitive Deficits in a Mouse Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[73]  P. Caramelli,et al.  Chemokines in CSF of Alzheimer's disease patients. , 2011, Arquivos de neuro-psiquiatria.

[74]  K. Blennow,et al.  Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility , 2011, NeuroMolecular Medicine.

[75]  S. Jo,et al.  Identification of peripheral inflammatory markers between normal control and Alzheimer's disease , 2011, BMC neurology.

[76]  Joseph Beyene,et al.  Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. , 2011, Journal of clinical epidemiology.

[77]  S. Rivest,et al.  CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[78]  E. Porcellini,et al.  Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration , 2011, Biogerontology.

[79]  Georg Kemmler,et al.  Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[80]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[81]  A. Keegan,et al.  Expression and regulation in the brain of the chemokine CCL27 gene locus , 2010, Journal of Neuroimmunology.

[82]  Murray Grossman,et al.  Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.

[83]  Monique Breteler,et al.  Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.

[84]  G. Halliday,et al.  Monocyte Chemoattractant Protein‐1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease , 2009, Brain pathology.

[85]  Min-Jeong Shin,et al.  Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. , 2008, Immunology letters.

[86]  Chulhee Choi,et al.  Multiplex Analysis of Cytokines in the Serum and Cerebrospinal Fluid of Patients With Alzheimer's Disease by Color-Coded Bead Technology , 2008, Journal of clinical neurology.

[87]  Joseph Beyene,et al.  The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: A simulation study , 2008 .

[88]  J. Lee,et al.  Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease , 2008, Neuroscience Letters.

[89]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[90]  Kuan Luan,et al.  Association between the macrophage inflammatory protein-l alpha gene polymorphism and Alzheimer's disease in the Chinese population , 2008, Neuroscience Letters.

[91]  Stavros J. Baloyannis,et al.  Systemic immune aberrations in Alzheimer's disease patients , 2008, Journal of Neuroimmunology.

[92]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[93]  Claudius Mueller,et al.  Increased production of inflammatory cytokines in mild cognitive impairment , 2007, Experimental Gerontology.

[94]  A. Lustig,et al.  Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. , 2007, Experimental cell research.

[95]  N. Bresolin,et al.  Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease , 2006, Neurobiology of Aging.

[96]  N. Bresolin,et al.  Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. , 2006, Archives of neurology.

[97]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[98]  B. Premack,et al.  Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 , 2005, The Journal of Immunology.

[99]  N. Bresolin,et al.  MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels , 2004, Neurobiology of Aging.

[100]  J. Verhoef,et al.  Amyloid-β-induced chemokine production in primary human macrophages and astrocytes , 2002, Journal of Neuroimmunology.

[101]  Weiqi Wang,et al.  Cutting Edge: The Orphan Chemokine Receptor G Protein-Coupled Receptor-2 (GPR-2, CCR10) Binds the Skin-Associated Chemokine CCL27 (CTACK/ALP/ILC)1 , 2000, The Journal of Immunology.

[102]  E. Bosmans,et al.  Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT , 1998, Aging.

[103]  P. Mecocci,et al.  Cognitive Decline and Alzheimer's Disease in Old Age: A Sex-Specific "Cytokinome Signature". , 2019, Journal of Alzheimer's disease : JAD.

[104]  A. Korczyn.  Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment. , 2016, Parkinsonism & related disorders.

[105]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[106]  D. Gambi,et al.  Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[107]  C. Laske,et al.  Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? , 2008, Journal of Alzheimer's disease : JAD.

[108]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..